These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7809890)

  • 1. [Tumor marker analyses--valuable tools if used correctly].
    Børmer OP; Paus E; Nustad K; Theodorsen L
    Tidsskr Nor Laegeforen; 1994 Nov; 114(28):3317-20. PubMed ID: 7809890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumor markers (advances and limits)].
    Gomes FR
    Acta Med Port; 1997 Jan; 10(1):75-80. PubMed ID: 9245182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process?
    Ebert W; Muley T; Drings P
    Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What are tumor markers, and what is their value?].
    von Kleist S
    Wien Klin Wochenschr; 1989 Jul; 101(14):459-63. PubMed ID: 2672605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human tetranectin: methodological and clinical studies.
    Høgdall CK
    APMIS Suppl; 1998; 86():1-31. PubMed ID: 9868384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histopathology and tumor markers].
    Kijima H; Ueyama Y; Osamura Y
    Rinsho Byori; 2003 Dec; 51(12):1203-15. PubMed ID: 14743744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour marker measurements in the diagnosis and monitoring of breast cancer.
    Cheung KL; Graves CR; Robertson JF
    Cancer Treat Rev; 2000 Apr; 26(2):91-102. PubMed ID: 10772967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Future prospects for the use of tumor markers].
    Grunicke H
    Wien Klin Wochenschr; 1989 Jul; 101(14):472-5. PubMed ID: 2672607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokeratin 20 is not a tissue-specific marker for the detection of malignant epithelial cells in the blood of colorectal cancer patients.
    Bustin SA; Gyselman VG; Siddiqi S; Dorudi S
    Int J Surg Investig; 2000; 2(1):49-57. PubMed ID: 12774338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
    Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 'Sentinel Node' Concept: More Questions Raised than Answers Provided?
    Schlag PM
    Oncologist; 1998; 3(5):VI-VII. PubMed ID: 10388128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour marker prescriptions for cancer screening in the Hellenic primary care.
    Vittoraki A; Alexiou G; Karakatsanis A; Mauri D; Xilomenos A; Zacharias G; Koukourakis G; Hrysovalantou-Marsoni E; Milousis A; Athanasiadou M; Chasioti D
    Eur J Cancer Care (Engl); 2007 Jan; 16(1):86-9. PubMed ID: 17227357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum tumour markers in clinical practice. Some general aspects.
    Kvinnsland S
    Scand J Clin Lab Invest Suppl; 1991; 206():6-11. PubMed ID: 1947761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of tumour markers in monitoring and follow-up of colorectal cancer patients].
    Beczássy E; Ottó S; Vámosi Nagy I
    Magy Onkol; 2004; 48(1):57-61. PubMed ID: 15105897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor marker concentrations in normal and malignant tissues of colorectal cancer patients and their prognostic relevance.
    Gebauer G; Müller-Ruchholtz W
    Anticancer Res; 1997; 17(4B):2939-42. PubMed ID: 9329569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of cytokeratins and additional markers in undifferentiated lymph node metastases of the neck.
    Bartel-Friedrich S; Friedrich RE; Holzhausen HJ
    Anticancer Res; 2000; 20(6D):4931-40. PubMed ID: 11326642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
    Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.